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OBJECTIVE: Diagnosis of breast cancer in young patients (≤35) correlates with a worse prognosis compared to
their older counterparts (N35). The aim of this study is to evaluate the relevance of clinical-pathologic factors and
prognosis in young (≤35) breast cancer patients. METHODS: One hundred thirty-two patients of operable breast
cancer who were younger than 35 are analyzed in this study. They were treated in our hospital between January
2006 and December 2012. Patients are classified into four molecular subtypes based on the immunohistochem-
ical profiles of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2
(HER2), and Ki-67. Clinical and pathologic factors have been combined to define a specific classification of three
risk levels to evaluate the prognosis of these young women. RESULTS: Patients whose ages are less than 30 have
poorer prognosis than patients whose ages are between 31 and 35. The status of lymph nodes post-surgery
seems to be the only factor related to patient age in young patients. The patients in level of ER+ or PR+ and
HER2−/+ status have the worst prognosis in hormone receptor–positive breast cancer. Group 3 in risk factor
grouping has the poorer prognosis than the other two groups. CONCLUSIONS: Patient age and axillary lymph
nodes post-surgery are the independent and significant predictors of distant disease-free survival, local
recurrence-free survival, and overall survival. The absence of PR relates to poor prognosis. The risk factor
grouping provides a useful index to evaluate the risk of young breast cancer to identify subgroups of patients with
a better prognosis.
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Breast cancer is uncommon in young women and correlates with a less
favorable prognosis; still it is the most frequent cancer in women under
40. Around 6.6% of all breast cancer cases are diagnosed in women less
than 40 years old, 2.4% in women less than 35, and 0.65% in women
less than 30 [1,2]. However, in China, the proportion of patients in the
age group of less than 35 was reported much higher [3].
On the basis of various prospective and retrospective studies, age is an
independent prognostic factor with worse survival; however, this issue is
now considered controversial. A great number of reports showed that
young breast cancer patients have more aggressive features, such as
biologically more ER negative [4–7], higher histologic grade, and more
triple-negative subtype [8,9]. Yet other studies have attributed the
inferior outcome of young age to the more advanced presentation at
diagnosis, including higher rates of axillary lymph node positivity andlarger tumor size [10–13]. Others have postulated that the effect of
differential gene expression between different age groups might play a
role [6,14]. However, all the above studies demonstrated that young
breast cancer patients have early recurrence with shorter disease-free
survival and overall survival (OS) compared with older patients.
1931 patients with primary 
breast cancer were treated 
between 2006 and 2012
1799 patients aged >35
were not in our study
132 patients aged ≤35 were 
in our study
12 patients were ductal 
carcinoma in situ
114 patients were 
invasive ductal breast 
cancer
6 patients were invasive 
lobular/metaplastic 
breast cancer 
35 patients received 
breast conservation
surgery
97 patients received 
breast mastectomy
Figure 1. Patient selection, pathologic diagnosis, and surgical procedure.
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receptor–positive breast cancer is also the main subtype in young
patients. In this study, we divided hormone receptor–positive breast
cancer and invasive ductal carcinomas into different risk levels to
evaluate the prognosis of young patients.
Materials and Methods
Patients
This study was approved by the institutional review board (IRB) of
Harbin Medical University. One thousand nine hundred thirty-one
patients who were initially diagnosed with breast cancer between
2006 and 2012 by surgical resection were retrieved from the Second
Affiliated Hospital, Harbin Medical University. Among those
patients, a total of 132 patients younger than age 35 was included
in this analysis. The patient selection process, pathologic diagnosis,
and surgical procedure are shown in Figure 1. Tumor size and lymph
nodes were assessed using the seventh edition of the American Joint
Committee on Cancer staging manual [15].
Molecular Subtypes and Treatment
Immunohistochemical assay was used to test for the expression of
ER, PR, HER2, and Ki-67. The cutoff value for ER positivity was
defined as ≥10% of tumor cells with nuclear staining; PR positivity
was defined as ≥20% of tumor cells with nuclear staining. The
immunohistochemical staining for HER2 was scored as 0, 1+, 2+, or3+ according to standard criteria [16]. Scores of 0 and 1+ were
considered negative and 3+ was considered HER2-positive. When a
score of 2+ was found, additional fluorescence in situ hybridization
(FISH) testing was done to establish HER2 gene amplification status.
A positive result was defined as an HER2 gene/chromosome 17 ratio
of larger than 2.0. The Ki-67 positive was defined as ≥14%, and
negative was defined as b14% [17]. The subtype was proposed to
separate luminal A (ER+, PR+, HER2−, Ki-67 b 14%), luminal B
(ER+ or PR+,HER2−; ER+, PR+,HER2−, Ki-67 ≥ 14%; ER+/PR+,
HER2+), HER2-enriched (ER-, PR−, HER2+), and triple-negative
(ER−, PR−, HER2−) [18].
Nineteen patients who were hormone receptor positive and Ki-67
b14% in post-surgery cancers only received 5 years of adjuvant
endocrine therapy, whereas hormone receptor positive and Ki-67 ≥
14% received adjuvant/neoadjuvant chemotherapy and endocrine
therapy. Patients who were positive for axillary lymph node following
surgery (n ≥ 3) and patients who received breast conservation surgery
received radiation therapy, whereas patients positive for axillary
lymph node following surgery (n ≥ 3) and patients who received
breast conservation surgery received radiation therapy.
Classification of Hormone Receptor–Positive Breast Cancer
Although there have been more triple-negative and HER2-enriched
subtypes, hormone receptor–positive breast cancer is still the main
subtype in young patients. ER+ and/or PR+ breast cancer is a highly
heterogeneous disease comprising different histology, gene expression
Table 1. Clinical-Pathologic Characteristics and Outcome
Total Local Relapse Distant Relapse Died of Disease LRFS DDFS OS
N (%) N (%) N (%) N (%) P HR 95% CI P HR 95% CI P HR 95% CI
Patient age
≤30 43 (32.58) 25 (46.30) 21 (46.67) 19 (59.38) .0004 0.37 0.22-0.64 .0030 0.41 0.23-0.74 .0002 0.26 0.13-0.53
31-35 89 (67.42) 29 (53.70) 24 (53.33) 13 (40.63)
ER status
+ 89 (67.42) 36 (66.67) 24 (53.33) 17 (53.13) .7804 0.92 0.52-1.63 .0161 0.49 0.27-0.88 .0460 0.49 0.24-0.99
− 43 (32.58) 18 (33.33) 21 (46.67) 15 (46.88)
PR status
+ 86 (65.15) 33 (61.11) 20 (44.44) 16 (50.00) .0677 0.60 0.34-1.04 b .0001 0.29 0.16-0.52 .0050 0.37 0.18-0.74
− 46 (34.85) 21 (38.89) 25 (55.56) 16 (50.00)
HER2 status
+ 37 (28.03) 22 (40.74) 22 (48.89) 17 (53.13) .0113 2.02 1.17-3.48 .0007 2.77 1.54-4.98 .0040 2.79 1.39-5.60
− 91 (68.94) 32 (59.26) 23 (51.11) 15 (46.88)
NA 4 (3.03) 0 (0.00) 0 (0.00) 0 (0.00)
Diagnosis
DCIS 12 (9.09) 0 (0.00) 0 (0.00) 0 (0.00) .0808 1.95 0.92-4.11 .1000 1.95 0.88-4.34 .1140 2.22 0.83-5.97
IDC 114 (86.36) 52 (96.30) 43 (95.56) 30 (93.75)
Other 6 (4.55) 2 (3.70) 2 (4.44) 2 (6.25)
Tumor grade
1 9 (6.82) 2 (3.70) 1 (2.22) 1 (3.13) b .0001 3.97 2.28-6.91 b .0001 4.03 2.26-7.19 b .0001 4.59 2.28-9.25
2 74 (56.06) 27 (50.00) 21 (46.67) 11 (34.38)
3 31 (23.48) 23 (42.59) 21 (46.67) 18 (56.25)
NA 18 (13.64) 2 (3.70) 2 (4.44) 2 (6.25)
Tumor size
T1 35 (26.52) 4 (7.41) 6 (13.33) 3 (9.38) b .0001 4.53 2.96-6.92 b .0001 2.86 1.94-4.22 b .0001 3.14 2.00-4.93
T2 73 (55.30) 29 (53.70) 20 (44.44) 15 (46.88)
T3 21 (15.91) 18 (33.33) 16 (35.56) 11 (34.38)
T4 3 (2.27) 3 (5.56) 3 (6.67) 3 (9.38)
Lymph nodes post-surgery
pN0 65 (49.24) 11 (20.37) 9 (20.00) 5 (15.63) b .0001 2.87 2.20-3.79 b .0001 2.71 2.04-3.59 b .0001 2.79 2.00-3.90
pN1 31 (23.48) 12 (22.22) 9 (20.00) 6 (18.75)
pN2 18 (13.64) 13 (24.07) 11 (24.44) 5 (15.63)
pN3 18 (13.64) 18 (33.33) 16 (35.56) 16 (50.00)
Ki-67 status
+ 84 (63.64) 40 (74.07) 38 (84.44) 26 (81.25) .0243 2.04 1.10-3.78 .0015 3.71 1.65-8.32 .0069 3.90 1.45-10.466
− 44 (33.33) 14 (25.93) 7 (15.56) 6 (18.75)
NA 4 (3.03) 0 (0.00) 0 (0.00) 0 (0.00)
Molecular subtype
Luminal A 8 (6.06) 2 (3.70) 5 (11.11) 2 (6.25) .4532 1.11 0.85-1.45 .0035 1.51 1.14-1.98 .0157 1.52 1.08-2.13
Luminal B 27 (20.45) 6 (11.11) 1 (2.22) 0 (0.00)
HER2-enriched 66 (50.00) 39 (72.22) 30 (66.67) 24 (75.00)
Triple-negative 10 (7.58) 0 (0.00) 0 (0.00) 0 (0.00)
NA 21 (15.91) 7 (12.96) 9 (20.00) 6 (18.75)
Abbreviations: DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma.
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responses to systemic treatment [19–22]. However, despite ongoing
international efforts to improve Ki-67 testing, including recommenda-
tions on pre-analytical and analytical issues, interpretation, and scoring
[23], a recent Ki-67 reproducibility study involving experienced
pathologists showed significant interobserver variability [24]. In our
study, we divided hormone receptor–positive breast cancer into three
levels regardless of the status of Ki-67 to evaluate the prognosis of young
patients: level 1—ER+, PR+, HER2−; level 2—ER+, PR+, HER2+;
level 3—ER+ or PR+, HER2−/+. Patients with level 2 and level 3
tumors received more chemotherapy than the level 1 subgroup. The
level 1 subgroup was treated with less chemotherapy and more
endocrine therapy than the other subgroups.Definition of Important Risk Factors
According to the important risk factors (ER, PR, HER2, and
Ki-67status, tumor grade, and lymph nodes post-surgery), 114 patients
were divided into three groups. Group 1's score is from 1 to 4, group 2's
score is from 5 to 6, and group 3's score is from 7 to 10. Tumors in the
three different groups were calculated as immunohistochemical results(ER−, PR−, HER2+, and Ki-67+, one point each) + tumor grade
(grade 1 tumor equals one point, and so on) + lymph nodes post-surgery
(score: 0 for no positive node, 1 for 1-3 nodes, 2 for 4-9 nodes, and 3
for ≥10 nodes). Groups 1, 2, and 3 were categorized as low risk,
medium risk, and high risk, respectively.
Statistical Analysis
The study comprised two parts: the univariate and the multivariate
analyses. In the univariate section, the studied factors were analyzed
through the time-to-event endpoints. Distant disease-free survival
(DDFS) was defined as the time interval between surgery and the first
documented distant relapse, death, or last follow-up. Local
recurrence-free survival (LRFS) was defined as the time interval
between surgery and the first documented local recurrence, death, or
last follow-up. OS was defined as the time between surgery and death
or last follow-up, which ever occurred first. For both endpoints, the
median survival time were estimated for all variables (patient age, ER
status, PR status, HER2 status, tumor grade, tumor size, lymph nodes
post-surgery, Ki-67 status, molecular subtype, hormone receptor–
positive grouping, and risk grouping). The median follow-up is
summarized by its median and interquartile range.
Table 2. Clinical-Pathologic Characteristics and Patient Age
Total ≤30 31-35 χ2 P Median Survival Time (Months)
N (%) N (%) N (%) LRFS DDFS OS
ER status
+ 89 (67.42) 30 (69.77) 59 (66.29) 0.1594 .6897 81 N99 92
− 43 (32.58) 13 (30.23) 30 (33.71) 78 66 85
PR status
+ 86 (65.15) 26 (60.47) 60 (67.42) 0.6169 .4322 83 N99 N99
− 46 (34.85) 17 (39.53) 29 (32.58) 59 49 92
HER2 status
+ 37 (28.03) 14 (32.56) 23 (25.84) 2.4198 .2982 56 54 89
− 91 (68.94) 29 (67.44) 62 (69.66) 83 N99 N99
NA 4 (3.03) 0 (0.00) 4 (4.49) N80 N80 N80
Diagnosis
DCIS 12 (9.09) 3 (6.98) 9 (10.11) 1.1437 .5645 N85 N85 N85
IDC 114 (86.36) 37 (86.05) 77 (86.52) 78 N99 92
Others 6 (4.55) 3 (6.98) 3 (3.37) N72 N72 N72
Tumor grade
1 9 (6.82) 2 (4.65) 7 (7.87) 5.0097 .1711 N81 N83 N83
2 74 (56.06) 20 (46.51) 54 (60.67) 87 N99 N99
3 31 (23.48) 15 (34.88) 16 (17.98) 37 49 61
NA 18 (13.64) 6 (13.95) 12 (13.48) N85 N85 N85
Size of IC
T1 35 (26.52) 11 (25.58) 24 (26.97) 6.7839 .0791 N99 N99 N99
T2 73 (55.30) 19 (44.19) 54 (60.67) 78 N98 92
T3 21 (15.91) 11 (25.58) 10 (11.24) 33 39 63
T4 3 (2.27) 2 (4.65) 1 (1.12) 24 37 46
Lymph nodes post-surgery
pN0 65 (49.24) 23 (53.49) 42 (47.19) 12.0924 .0071 N96 N96 N96
pN1 31 (23.48) 7 (16.28) 24 (26.97) 83 N99 92
pN2 18 (13.64) 2 (4.65) 16 (17.98) 47 56 79
pN3 18 (13.64) 11 (25.58) 7 (7.87) 26 33 46
Ki-67 of IC
+ 84 (63.64) 32 (74.42) 52 (58.43) – .1229 75 67 89
− 44 (33.33) 11 (25.58) 33 (37.08) N99 N99 N99
NA 4 (3.03) 0 (0.00) 4 (4.49) N80 N80 N80
Molecular subtype
Luminal A 8 (6.06) 1 (2.33) 7 (7.87) 7.4842 .1124 N99 N99 N99
Luminal B 27 (20.45) 6 (13.95) 21 (23.60) 73 75 89
HER2-enriched 66 (50.00) 27 (62.79) 39 (43.82) N96 47 N96
Triple-negative 10 (7.58) 1 (2.33) 9 (10.11) N86 76 N86
NA 21 (15.91) 8 (18.60) 13 (14.61) N85 N85 N85
Abbreviation: IC, invasive carcinoma.
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prognosis analyses. Survival rates were estimated using the Kaplan-Meier
product limit method. Differences between survival curves were tested
using the log rank test. LRFS,DDFS, andOS interrelated predictors were
analyzed by Cox proportional hazards regression with univariate and
multiple regression models. Multivariate logistic regression analysis was
used to test the association of patient age, ER status, PR status, HER2
status, tumor grade, tumor size, lymph nodes post-surgery, Ki-67 status,
molecular subtype, hormone receptor–positive grouping, and risk
grouping to survival. The multiple Cox proportional hazards models
were also used to estimate the crude hazard ratios (HR) along with their
corresponding 95% confidence intervals (CIs). The Fisher exact test was
used to assess the relationship between the different age groups and the
clinical and pathologic factors. Statistical analyses were performed using
SAS (version 9.2), and GraphPad Prism 5 was used for drawing survival
rates. All P values b .05 were considered statistically significant.
Results
Clinical-Pathologic Factors PredictOutcome andClinical-Pathologic
Factors and Patient Age
We reported data of 132 patients who were initially diagnosed with
breast cancer. The clinical and pathologic characteristics of the studypopulation are summarized in Table 1. The median age of patients
was 32. The median follow-up time was 67 months, with 32 deaths,
45 distant metastases, and 54 local recurrences. Median survival time
of all predictors is shown in Table 6. Patient age, HER2 status, tumor
grade, tumor size, lymph nodes post-surgery, and Ki-67 status were
associated with LRFS; patient age, ER status, PR status, HER2 status,
tumor grade, tumor size, lymph nodes post-surgery, Ki-67 status, and
molecular subtype were associated with DDFS and OS. In Table 2,
compared with women aged 31 to 35, women younger than 30 years
old had more positive lymph nodes post-surgery (P = .0071). Hence,
in our study, other clinical pathologic factors were not correlated with
patient age in young women except lymph nodes post- surgery.
In our study, patient age (≤35) was an independent predictor of
patient’s prognosis both in univariate and multivariate analyses
(Figure 2, A–C, and Tables 1 and 5). Patients younger than 30 have
poorer prognosis compared to patients of age between 31 and 35.
Hormone Receptor–Positive Breast Cancer and Outcome
Among the classification schemes evaluated, three levels of hormone
receptor–positive breast cancer predicted LRFS, DDFS, and OS in our
cohort (Figure 3, A–C, and Table 3). The level of ER, PR, and HER2
status was associated with LRFS (P b .0001, HR: 2.17, 95% CI:
1.58-2.98), DDFS (P b .0001, HR: 2.29, 95%CI: 1.84-4.23), and OS
Figure 2. Patient age with outcome. (A) Patient age in relation to
LRFS by Kaplan-Meier survival analysis. Median survival time:
patients ≤30 years old, 50 months; patients 31 to 35 years old, 87
months. (B) Patient age in relation to DDFS by Kaplan-Meier
survival analysis. Median survival time: patients ≤30 years old, 65
months; patients 31 to 35 years old, N99 months. (C) Patient age in
relation to OS by Kaplan-Meier survival analysis. Median survival
time: patients ≤30 years old, 89 months; patients 31 to 35 years
old, 92 months.
Figure 3. ER, PR, and HER2 status with outcome. (A) ER, PR, and
HER2 status in relation to LRFS by Kaplan-Meier survival analysis.
Median survival time: level 1 with 83 months; level 2 with 46
months; level 3 with 37.5 months. (B) ER, PR, and HER2 status in
relation to DDFS by Kaplan-Meier survival analysis. Median survival
time: level 1 with N99 months; level 2 with 67 months; level 3 with
43 months. (C) ER, PR, and HER2 status in relation to OS by
Kaplan-Meier survival analysis. Median survival time: level 1 with
N99 months; level 2 with 89 months; level 3 with 70 months.
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carcinoma patients in young women with best prognosis (ER+, PR+,
HER2−), and it also identified the group of carcinoma patients who
have the worst prognosis (ER+ or PR+, HER2−/+) in hormone
receptor–positive breast cancer. The level of hormone receptor–positive
breast cancer is a significant independent predictor of LRFS, DDFS,
and OS.Different Risk Groupings Predict Survival
This classification proposed the important risk factors resulting in
significantly different LRFS, DDFS, andOS values (all P b .0001). The
patients in group 3 were considered to have the worst LRFS, worst
DDFS, and worst OS in our cohort (Figure 4,A–C, and Table 4). All of
19 patients in group 3 had distant metastases, and 17 of themwith local
recurrences have died. Hence, the risk grouping is considered a
significant independent predictor of LRFS, DDFS, and OS.
Multivariate Analysis for Predicting Survival
In our study, a multivariate analysis was undertaken to determine
which factors were independent or significant predictors of patient’s
survival using the Cox proportional hazards regression model. The
Table 3. ER, PR, and HER2 Status with Outcome
ER,PR, and
HER2 Status
Total Local Relapse Distant Relapse Died of Disease LRFS DDFS OS
N (%) N (%) N (%) N (%) P HR 95% CI P HR 95% CI P HR 95% CI
ER+, PR+, HER2− 55 (60.44) 16 (35.56) 7 (22.58) 4 (16.67) b .0001 2.17 1.57-2.98 b .0001 2.79 1.84-4.23 b .0001 2.95 1.80-4.85
ER+, PR+, HER2+ 12 (13.19) 8 (17.78) 6 (19.35) 5 (20.83)
ER+/PR+, HER2−/+ 24 (26.37) 21 (46.67) 18 (58.06) 15 (62.50)
Figure 4. Risk factor grouping with outcome. (A) Risk grouping in
relation to LRFS by Kaplan-Meier survival analysis. Median survival
time: group 1 with N99 months; group 2 with 74 months; group 3
with 27 months. (B) Risk grouping in relation to DDFS by
Kaplan-Meier survival analysis. Median survival time: group 1
with N99 months; group 2 with 67 months; group 3 with 33
months. (C) Risk grouping in relation to OS by Kaplan-Meier survival
analysis. Median survival time: group 1 with N99 months; group 2
with 89 months; group 3 with 46 months.
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tumor size, diagnosis, tumor grade, lymph nodes, ER, PR, HER2,
Ki-67 status, molecular subtypes, hormone receptor–positive breast
cancer grouping, and risk groups.
The results of interrelated predictor analysis of DDFS, LRFS, and
OS are shown in Table 5. Patient age, lymph nodes, PR status,
molecular subtypes, and risk groups were the interrelated predictors of
DDFS in young patients. Patient age, lymph nodes, PR status, and
tumor size were the interrelated predictors of LRFS in young patients.
Patient age, lymph nodes, PR status, Ki-67 status, and tumor size
were the interrelated predictors of OS in young patients. It can be
seen that PR+ as well as patients at the age older than 30 were
interrelated predictors of better DDFS, LRFS, and OS. The
increasing grade of lymph nodes, risk groups, and molecular subtype
were influence predictors of worse DDFS. The increasing grade of
lymph nodes and tumor size were interrelated predictors of worse
LRFS. The increasing grade of lymph nodes, tumor size, and Ki-67+
were interrelated predictors of worse OS.
Discussion
On the basis of the various prospective and retrospective studies
performed in the last two decades, it has been generally accepted that
young age (≤35) at diagnosis correlates with a worse clinical outcome
compared to their older counterparts (N35). However, few studies had
paid attention to the fact that the difference between clinical and
pathologic factors in young patients (≤35) might have different
prognoses. In our study, we choose some clinical and pathologic factors
that may affect the prognosis of young breast cancer patients in
univariate and multivariate analyses. Patient age, HER2 status, tumor
grade, tumor size, lymph nodes post-surgery, and Ki-67 status were
associated with LRFS; patient age, ER status, PR status, HER2 status,
tumor grade, tumor size, lymph nodes post-surgery, Ki-67 status, and
molecular subtype were associated with DDFS and OS. Patient age of
31 to 35 years and ER+ and PR+ were associated with better prognosis;
other factors were associated with worse prognosis (Tables 1 and 6).
Patient age for this cohort was statistically significant for DDFS,
LRFS, and OS in both and univariate and multivariate analyses
(Tables 1 and 5). Patients whose ages are less than 30 have poorer
prognosis compared with patients of ages between 31 and 35. We also
show the correlation between patient age and clinicopathologic
factors. The results have shown that patients younger than 35 only
related to the status of lymph nodes post-surgery. In other words,
patients younger than 30 are related with more axillary lymph node
positivity compared with patients of age between 31 and 35 (Table 2).
Our study confirmed that the number of positive lymph nodes
after surgery is a very important parameter for the long-term outcome.
The number of involved lymph nodes is relevant to long-term
outcome (Tables 1 and 5). More positive lymph nodes after surgery
correlated with worse DDFS, LRFS, and OS by Kaplan-Meier and
Cox regression analyses. At the same time, the status of lymph nodes
post-surgery was the only related factor to patient age in young
Table 4. Risk Factors Grouping with Outcome
Grouping Total Local Relapse Distant Relapse Died of Disease LRFS DDFS OS
N (%) N (%) N (%) N (%) P HR 95% CI P HR 95% CI P HR 95% CI
Group 1 48 (42.10) 10 (19.23) 3 (6.98) 2 (6.67) b .0001 3.67 2.45-5.50 b .0001 7.90 4.57-13.65 b .0001 7.95 4.08-15.48
Group 2 47 (41.23) 25 (48.08) 21 (48.84) 11 (36.67)
Group 3 19 (16.67) 17 (32.69) 19 (44.19) 17 (56.67)
Table 6. Median Survival Time of All Predictors
Median Survival (Months)
LRFS DDFS OS
Patient age ≤30 50 65 89
31-35 87 N99 92
ER status + 81 N99 92
− 78 66 85
PR status + 83 N99 N99
− 59 49 92
HER2 status + 56 54 89
− 83 N99 N99
NA N80 N80 N80
Diagnosis DCIS N85 N85 N85
IDC 78 N99 92
Other N72 N72 N72
Tumor grade 1 N81 N83 N83
2 87 N99 N99
3 37 49 61
NA N85 N85 N85
Size of IC T1 N99 N99 N99
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younger than 30 years is one of the reasons of the poorer outcome in
patients younger than 30 compared to patients of age between 31 and
35 (Figure 2, A–C, and Table 2).
It is well established that there are at least four main subtypes
of breast cancer based on different patterns of gene expression, and
they have a considerable impact on prognosis [19,20]. Many studies
have confirmed the increasing proportion of ER/PR negativity,
HER2-enriched subtype, and high grade in young women with breast
cancer [6]. Although there have been more triple-negative and
HER2-enriched subtypes, hormone receptor–positive breast cancer
remains to be the major subtype among young patients. Luminal A
tends to have the best prognosis; the HER2-enriched and the
triple-negative tumors both confer worse prognosis [19]. In our study,
level 1 (ER+, PR+, HER2−) in hormone receptor–positive breast cancer
has better prognosis compared with other levels (triple-positive and ER+
or PR+, HER2−/+). The patients in level 3 have the worst prognosis in
hormone receptor–positive breast cancer (Table 3), and the median
survival time was shorter than triple-negative and HER2-enriched
subtypes in LRFS, DDFS, and OS (Figure 3, A–C, and Tables 2 and 6).
The absence of PR may be a marker of aberrant growth factor
signaling and, consequently, one mechanism for anti-estrogen
resistance [25,26]. ER+/PR− tumors as defined by RNA profiling
represent a distinct subset of breast cancer with aggressive features and
poor outcome despite being clinically ER+ [27]. The results of the
recent study indicate that PR is an important prognostic factor to
properly define subgroups with different prognoses within the
hormone receptor–positive subtype, irrespective of HER2 overex-
pression or amplification. The prognostic and predictive values of PR
have been, for a long time, ascribed to the dependence of PR
expression on ER activity, with the absence of PR reflecting a
nonfunctional ER and resistance to hormonal therapy [25,28,29]. In
our cohort, PR+ was considered as a better prognosis factor both in
univariate and multivariate analyses except in LRFS univariate
analysis. The result showed that the absence of PR related to poorerTable 5. Outcome in Multivariate Analysis
Outcome Influence Factor β P HR 95% CI
Lower Limit Upper Limit
DDFS Patient age −0.97 .0325 0.38 0.18 0.92
PR status −1.44 .0020 0.24 0.10 0.59
Lymph nodes post-surgery 0.89 .0034 2.42 1.34 4.38
Molecular subtype 2.32 .0392 10.13 1.12 91.47
Grouping 1.01 .0295 2.74 1.11 6.78
LRFS Patient age −1.12 .0014 0.33 0.16 0.65
PR status −1.42 .0002 0.24 0.11 0.51
Tumor size 1.33 b .0001 3.78 2.14 6.68
Lymph nodes post-surgery 0.75 b .0001 2.12 1.49 3.02
OS Patient age −1.81 .0004 0.16 0.06 0.45
PR status −1.89 .0006 0.15 0.05 0.44
Tumor size 0.78 .0312 2.18 1.07 4.44
Lymph nodes post-surgery 0.76 .0015 2.13 1.34 3.40
Ki-67 status 1.78 .0120 5.94 1.48 23.82prognosis, and PR status was a statistically significant prognosis factor
in long-term follow-up.
In this article, we focused on prognostic factors and survival.
Several prognostic factors have been identified in invasive breast
cancer. As we observed in our works and in studies of others, ER,
PR, HER2, Ki-67 status, tumor grade, and lymph nodes post-surgery
were the significant prognostic factors. Indeed, the most powerful
prognostic factor was axillary lymph nodes post-surgery. In addition,
we focused on tumor grading, finding that survival was worse in
patients with poorly differentiated tumors (grades II and III)
compared with that of patients with well-differentiated grade I
tumors. Globally, other four factors with axillary lymph nodes
post-surgery and tumor grade have been combined to create a single
prognostic parameter. This combination classification has been
divided into three groups. As shown in Table 4, the risk of local
recurrence has increased 3.67 times; the risk of distant relapse hasT2 78 N98 92
T3 33 39 63
T4 24 37 46
Lymph nodes post-surgery pN0 N96 N96 N96
pN1 83 N99 92
pN2 47 56 79
pN3 26 33 46
Ki-67 of IC + 75 67 89
− N99 N99 N99
NA N80 N80 N80
Molecular subtype Luminal A N99 N99 N99
Luminal B 73 75 89
HER2-enriched N96 47 N96
Triple-negative N86 76 N86
NA N85 N85 N85
ER, PR, and HER2 status ER and PR+, HER2− 83 N99 N99
ER/PR+, HER2−/+ 37.5 43 70
ER and PR+, HER2+ 46 67 89
Grouping Group 1 N99 N99 N99
Group 2 74 67 89
Group 3 27 33 46
272 Prognosis and Clinical-Pathologic Factors Zhao et al. Translational Oncology Vol. 8, No. 4, 2015increased 7.90 times; the risk of death has increased 7.95 times
(Figure 4, A–C, and Table 4); and the median survival time in level
3 was shorter than level 1 and level 2 in LRFS, DDFS, and
OS (Table 6). This classification of important risk factors resulting
in significantly different LRFS, DDFS, and OS (all P b .0001)
should help us in the selection of subgroups of patients for further
adjuvant treatment.
Conclusions
In conclusion, this study shows that patient age in young women and
axillary lymph nodes post-surgery are the independent and significant
predictors in DDFS, LRFS, and OS. The absence of PR related to
poorer prognosis, and PR status was a statistically significant
prognosis factor in long-term follow-up. The risk factor grouping
provided evidence for prognostic significance and appears to be
applicable to invasive breast cancer. This classification may offer a
useful index to evaluate the risk of young breast cancer to identify
subgroups of patients with better prognosis.
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